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Abstract
Background & Aims—The prevalence of non-alcoholic fatty liver disease (NAFLD) and 
steatohepatitis (NASH) is increasing at an alarming rate. The role of bile acids in the development 
and progression of NAFLD to NASH and cirrhosis is poorly understood. This study aimed to 
quantify the bile acid metabolome in healthy subjects and patients with non-cirrhotic NASH under 
fasting conditions and after a standardized meal.
Methods—Liquid chromatography tandem mass spectroscopy was used to quantify 30 serum 
and 16 urinary bile acids from 15 healthy volunteers and 7 patients with biopsy-confirmed NASH. 
Bile acid concentrations were measured at two fasting and four post-prandial timepoints following 
a high-fat meal to induce gallbladder contraction and bile acid reabsorption from the intestine.
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Results—Patients with NASH had significantly higher total serum bile acid concentrations than 
healthy subjects under fasting conditions (2.2- to 2.4-fold increase in NASH; NASH: 2595–3549 
μM and healthy: 1171–1458 μM) and at all post-prandial time points (1.7- to 2.2-fold increase in 
NASH; NASH: 4444–5898 μM and healthy: 2634–2829 μM). These changes were driven by 
increased taurine- and glycine-conjugated primary and secondary bile acids. Patients with NASH 
exhibited greater variability in their fasting and post-prandial bile acid profile.
Conclusions—Results indicate that patients with NASH have higher fasting and post-prandial 
exposure to bile acids, including the more hydrophobic and cytotoxic secondary species. Increased 
bile acid exposure may be involved in liver injury and the pathogenesis of NAFLD and NASH.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases 
in the Western world, and the incidence is rising concurrently with the increased prevalence 
of metabolic syndrome.[1] The more progressive form, non-alcoholic steatohepatitis 
(NASH), is characterized by advancing hepatocyte steatosis, ballooning, and inflammation, 
subsequently leading to fibrosis and cirrhosis.[2] The mechanisms behind the progression of 
NAFLD from simple steatosis to NASH to cirrhosis are not well understood. Previously, 
progression of NAFLD has been associated with genetic predisposition, insulin resistance, 
hepatic iron storage, as well as inflammatory events or mediators including adipokines, 
endotoxins and oxidative stress leading to apoptosis and necrosis.[3,4] Although the 
mechanisms precipitating release of inflammatory mediators or induction of cell death 
pathways are not fully understood, intestinal and hepatic handling of cytotoxic bile acids 
may be involved.
Primary bile acid species (cholate [CA] and chenodeoxycholate [CDCA]) are synthesized in 
the liver and stored in the gallbladder until ingestion of a high fat meal when they are 
released into the duodenum. In the intestine, bile acids are metabolized by bacteria to more 
hydrophobic bile acid species through dehydroxylation resulting in secondary bile acid 
species (deoxycholate [DCA] and lithocholate [LCA]) and/or deconjugation of hydrophilic 
groups (e.g., amino acids).[5–7] Ultimately the bile acids are reabsorbed and returned to the 
liver to repeat the highly efficient and tightly regulated cycle.[8] In addition to enteric 
metabolism by bacteria, primary and secondary bile acid species can be modified by hepatic 
addition of hydrophilic groups including hydroxyl (hyocholate [HCA], muricholate [MCA], 
and hyodeoxycholate [HDCA]) and/or amino acid moieties (taurine or glycine, abbreviated 
as T- and G- followed by the parent bile acid abbreviation [e.g., glycine conjugated cholate, 
GCA]).[8] Importantly, accumulation of bile acids within hepatocytes can cause cytotoxicity 
by inducing mitochondrial dysfunction and formation of reactive oxygen species, ultimately 
leading to apoptosis or necrosis. Generally, the more hydrophobic bile acid species (e.g., 
unconjugated secondary > conjugated primary) have greater cytotoxic effects.[3]
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Although supra-physiologic bile acid concentrations appear to be deleterious, activation of 
many key receptors including the G-protein coupled receptor, TGR5, farnesoid X receptor 
(FXR), and pregnane X receptor (PXR) indicate that bile acids may have far reaching 
endocrine functions.[9] In addition to regulation of de novo bile acid synthesis, activation of 
these receptors is involved in triglyceride, cholesterol and glucose homeostasis.[8–10] 
Interestingly, affinity for these important signaling receptors is dependent on species and 
conjugation status of the individual bile acids.[9] Due to these signaling properties and target 
selectivity achievable with minor physicochemical modification, bile acids and their close 
derivatives have become promising drug candidates for treating metabolic and hepatic 
diseases.[11] However, the role of individual bile acid species in energy homeostasis in 
relation to inflammation and cell death pathways is poorly understood.
Modification of hepatic bile acid metabolism and transporters[12–14] and/or the gut 
microbiome[6,15] in NAFLD may alter the predominant bile acid species thereby impacting 
post-prandial bile acid-dependent signaling and modulating hepatic inflammatory cascades. 
Examination of bile acid species in patients currently abstinent from ethanol with 
steatohepatitis and cirrhosis revealed decreased secondary bile acids excreted in the stool 
and increased glycine- and taurine-conjugated bile acids in the serum.[16] However, the 
impact of non-cirrhotic NASH on bile acid concentrations under fasting conditions, and in 
response to a standardized high fat meal stimulus and subsequent enterohepatic 
recirculation, has not been elucidated. Therefore, in this study a comprehensive array of bile 
acid species in the serum and urine were quantified under fasting conditions at two distinct 
clinic visits, and following a high-fat meal in patients with biopsy-confirmed NASH 
compared to healthy subjects.
Patients and Methods
Patients
Healthy subjects and patients with biopsy-confirmed NASH, between 18 and 65 years of 
age, and of any race and ethnicity, who reported drinking <20 g/day of alcohol, were 
enrolled in the study. The general inclusion and exclusion criteria were described previously.
[13] Briefly, inclusion criteria for healthy subjects and patients with NASH were: normal 
serum creatinine and total bilirubin levels; non-reactive hepatitis B antigen and hepatitis C 
antibody; no history of gastrointestinal surgery; and no ingestion of any over-the-counter or 
prescription medications or dietary supplements known to disturb bile acid metabolism, 
transport or enterohepatic cycling. Patients with NASH were recruited from the University 
of North Carolina at Chapel Hill (UNC-CH) hepatology clinic and were eligible for 
enrollment based on the following: biopsy-confirmed non-cirrhotic NASH with non-
alcoholic fatty liver disease activity score (NAS) >3[17]; BMI ≤45 kg/m2. Healthy 
volunteers were recruited from a pool of interested respondents to posted flyers, email 
messages and word of mouth, and were eligible if all of the following applied: normal 
alkaline phosphatase (ALP) and alanine transaminase (ALT) levels; HOMA-IR score <2.5; 
BMI ≤30 kg/m2. Effort was made to recruit a healthy subject cohort in a 2:1 fashion 
comparable to the NASH cohort with respect to age, sex, race, and ethnicity. Written 
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informed consent was obtained from all subjects. This study was approved by the UNC-CH 
Biomedical Institutional Review Board and published in ClinicalTrials.gov (NCT01766960).
Study Design
This single center, comparative cohort study evaluated the baseline fasting and post-prandial 
bile acid profile in healthy subjects and patients with NASH. Subjects were fasted overnight 
prior to the screening visit; screening labs and an initial bile acid sample were collected at 
the screening visit. Subsequently, subjects who met all inclusion/exclusion criteria fasted 
overnight prior to presenting to the Clinical and Translational Research Center at UNC-CH 
Hospitals. Following admission, subjects voided any urine, another fasting bile acid sample 
was collected, and an i.v. catheter was placed in each arm delivering 50 mL/hr of normal 
saline and lactated Ringer’s solution. Patients ate (within a 30-min period) a standardized 
breakfast sandwich containing 509 kcal, 27.2 g protein, 23.9 g fat, and 53.3 g carbohydrates 
designed to induce gallbladder contraction.[10,18] Blood (5–15 mL) was collected in 
untreated glass tubes every 30 min for 2 hours after the meal was finished; urine was 
collected and pooled over the 2-hour post-prandial period. Blood samples were allowed to 
clot for 30 to 60 min, and serum was separated, divided into aliquots and frozen. Serum and 
urine samples were stored at −80°C until analysis.
Sample Processing and Analysis
A total of 30 bile acid standards were available and obtained from Steraloids Inc. (Newport, 
RI). Stable isotope-labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, 
Canada). Sample preparation and bile acid quantification methodology were adapted from 
Xie et al.[19] Briefly, an internal standard solution containing 50 nM d4-CA, d4-UDCA and 
d4-LCA (C/D/N Isotopes, Quebec, Canada) was added to serum, urine or standard solution. 
After centrifugation, the supernatant was evaporated to dryness. The residue was 
reconstituted with 50:50 acetonitrile and water and filtered. A UPLC-MS/MS system 
(ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA) with VanGuard pre-column 
(2.1×5 mm) and heated ACQUITY BEH C18 1.7 μM column (2.1×100 mm) was used to 
quantify 30 bile acids in serum and urine. The mass spectrometer was operated in negative 
ion mode. The cone and collision energy for each bile acid used the optimized settings from 
QuanOptimize application manager (Waters Corp., Milford, MA). Calibration solutions 
containing all 30 analytes prepared at a series of concentrations in pooled naïve plasma 
depleted of bile acids using activated charcoal were used to generate calibration curves using 
TargetLynx application manager (Waters Corp., Milford, MA).
Data Analysis
The molar sum of all measured bile acids is reported as total bile acids. Total unconjugated 
and glycine- and taurine-conjugated bile acids were calculated as the sum of all 
unconjugated or glycine- or taurine-conjugated species of CA, CDCA, HCA, HDCA, MCA, 
DCA, LCA, and UDCA bile acid species. The total concentrations of primary, secondary 
and 6α-hydroxylated bile acid species were calculated by adding the molar concentrations of 
all conjugated and unconjugated species of CA and CDCA; DCA, LCA, and UDCA; and 
HCA, HDCA, and MCA, respectively. The relative abundance of each group of bile acid 
species was calculated as the total molar mass for that particular species divided by the total 
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bile acid concentration. Urinary bile acid species are presented as the total mass excreted 
over the 2-hour postprandial period calculated as the product of the concentration in urine 
and the volume of urine collected. The limit of quantification was 1 nM for all bile acid 
species except for a limit of 2 nM for GDCA and dehydro-, allo-, and iso-LCA, and a limit 
of 5 nM for 12-dehydro-HCA. Measured bile acid concentrations below the limit of 
quantification, but above the limit of detection were imputed as the limit of quantification; 
concentrations measured below the limit of detection were set to zero.
Statistical Analysis Strategy
Study population characteristics are presented as mean and standard deviation. Individual 
bile acid species and groups of bile acids are presented and graphed as mean and standard 
error. To compare the total post-prandial exposure to selected bile acids, the area under the 
serum concentration-time curve (AUC) from baseline on the study day to the 2-hour post-
prandial time point (AUCpost-prandial; AUCpp) was estimated using non-compartmental 
analysis techniques with linear trapezoidal algorithm (WinNonlin Phoenix, v. 6.3, Certara, 
St. Louis, MO). Cohort characteristics, bile acid concentrations at discrete time points and 
AUCpp comparisons relied on a two-tailed pooled-variance t-test procedure of size α=0.05 
using SAS (v. 9.3, SAS Institute, Inc., Cary, NC) and GraphPad Prism (v. 6.0 for Windows, 
GraphPad Software, La Jolla, CA). Due to the nature of this study and relatively small 
samples size, adjustment of statistical tests for multiple comparisons was not possible. 
According to the Shapiro-Wilk test, some individual and groups of bile acids were skewed 
and not normally distributed. Although the power to detect a difference using a parametric 
test with skewed data is decreased, all statistical comparisons were conducted similarly. 
Orthogonal partial least squares-discriminant analysis (OPLS-DA), a multivariate approach, 
was performed to visualize the bile acid metabolome in patients with NASH compared to 
healthy controls (SIMCA v. 13.0.3, Umetrics, Umeå, Sweden). OPLS-DA models were 




Twenty-two volunteers (15 healthy subjects and 7 patients with biopsy-confirmed NASH) 
were studied. In selecting healthy subjects, effort was made to recruit a control cohort 
comparable to the NASH cohort with respect to age, sex, race, and ethnicity. The 
demographic results (Table 1) were reported, in part, in association with a pharmacokinetic 
study conducted in some of these subjects.[13] As expected, patients with NASH weighed 
more and had a higher body mass index (BMI) than the healthy subjects. Serum creatinine 
was within normal limits for both groups, resulting in estimated glomerular filtration rates 
within normal limits for all subjects. Compared to healthy subjects, patients with NASH had 
higher serum alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglycerides, 
and decreased high-density lipoprotein cholesterol (HDL). Patients with NASH had 
increased insulin resistance as demonstrated by increased fasting glucose, insulin and leptin 
concentrations, as well as by homeostasis model for assessing insulin resistance (HOMA-
IR) scores; insulin and glucose levels were statistically significantly higher at all post-
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prandial time points with the exception of the insulin concentration 30 min after completion 
of the meal (data not shown). Serum osteopontin concentrations were increased in patients 
with NASH at all fasting and post-prandial time points, but these differences did not reach 
statistical significance. Biopsy results indicated that all NASH patients had a NAFLD 
activity score (NAS) of at least 4, with a maximum score of 6 and minimal to moderate (F0 
to F3) fibrosis (Table 1).
Fasting Circulating Bile Acid Concentrations
Total fasting serum bile acid concentrations in patients with NASH were increased 2.2 to 
2.4-fold compared to healthy subjects (Figure 1). As shown, this difference was due 
predominantly to higher concentrations of taurine- and glycine-conjugated bile acids. 
Taurine-conjugated bile acids increased by as much as 5.6-fold whereas glycine-conjugated 
bile acids increased to a lesser extent by as much as 3.2-fold. Individual serum bile acid 
concentrations under fasting conditions at screening and on the study day (T=0) are 
presented in Supplementary Table 1. Both primary and secondary bile acids were increased 
in patients with NASH (Figure 2, Supplementary Table 1). It is important to note that total 
secondary bile acid concentrations, which tend to be more hydrophobic and toxic, were 
statistically significantly higher in patients with NASH at both fasting serum collections 
(screening and T=0) by 2.3 to 2.5-fold compared to healthy subjects (Supplementary Table 
1).
Post-Prandial Circulating Bile Acid Concentrations and Urinary Bile Acid Excretion
Serum bile acid concentrations generally increased from baseline in both healthy subjects 
and patients with NASH following ingestion of the standardized high fat breakfast, 
consistent with gallbladder contraction and reabsorption of bile acids from the intestine. 
Patients with NASH exhibited a greater post-prandial increase in all bile acid groups except 
LCA and 6α-hydroxylated bile acids (Figure 2). Furthermore total post-prandial exposure 
measured by AUCpp of CDCA, DCA and UDCA species was statistically significantly 
increased in NASH patients after ingestion of the high fat meal (Figure 2). Interestingly, 
LCA did not exhibit the same increased post-prandial exposure between patients with NASH 
and healthy subjects compared to DCA. Separating the fasting and post-prandial circulating 
LCA concentrations by conjugation status revealed that patients with NASH had slightly 
increased unconjugated LCA exposure over the post-prandial period, whereas glycine- and 
taurine-conjugated LCA post-prandial exposure was decreased (Figure 3). This finding is 
contrary to the apparent increase in glycine and taurine conjugation patterns observed with 
most other serum bile acids.
Although total concentrations of the majority of bile acids were increased in patients with 
NASH, the relative abundance of each bile acid species (defined as the fraction of the total 
bile acid concentration represented by each species) was unchanged at both fasting baseline 
measurements and over the post-prandial period (Figure 4). The relative amount of bile acids 
excreted in the urine was slightly higher in patients with NASH (Table 2, Figure 5).
Ferslew et al. Page 6













Orthogonal Partial Least Squares-Discriminant Analysis
Separate OPLS-DA scores plots for the bile acids at each fasting and post-prandial sample 
were used to evaluate perturbations in the profile of individual bile acid species between 
patients with NASH and healthy subjects (Figure 6). OPLS-DA scores plots of the bile acids 
indicated that patients with NASH clearly separated from healthy subjects (cumulative Q2Y 
0.20 to 0.40). Under fasting conditions, healthy subjects were more tightly grouped and 
demonstrated less overall variability in the primary components of the bile acid profile 
compared to patients with NASH. The OPLS-DA plots are able to distinguish diseased 
patients from healthy subjects (Figure 6 Screening and Pre-Prandial). Over the post-prandial 
period, the cluster describing healthy subjects tended to expand (Figure 6 Post-Prandial), 
suggesting that the high fat meal induced a more pronounced change in the bile acid profile 
in the patients with NASH compared to healthy subjects.
Discussion
This study is the first to compare the serum bile acid profile in patients with non-cirrhotic 
NASH to healthy controls without evidence of insulin resistance under fasting conditions 
and following a high fat breakfast. The fasting serum bile acid profile in healthy subjects 
was almost identical to previous reports strengthening the validity of our methods and 
results.[5,20] This is likely due to the redundant cellular mechanisms and feedback loops 
governing de novo synthesis, hepatic and intestinal metabolism, hepatic excretion and 
intestinal reabsorption providing tight control of bile acid homeostasis.[8,15] However, in 
the presence of NASH, regulation of bile acid homeostasis appears to be disrupted. The 
fasting total serum bile acid concentrations were increased in patients with NASH by 
approximately 2-fold, driven by increases in glycine- and taurine-conjugated bile acids 
including increased secondary bile acid species. In similar studies evaluating bile acid 
concentrations in patients with cirrhotic NASH and rodent models, similar albeit 
exaggerated increases in systemic bile acids were observed compared to the present study, 
whereas primary and secondary bile acid concentrations were reduced in human stool 
samples.[16,21] Although stool concentrations were decreased, intrahepatic accumulation of 
the secondary bile acid DCA was increased in NASH.[22] Serum and urine DCA 
concentrations were statistically significantly increased in the present study. Overall, these 
findings suggest that multiple regulatory mechanisms involved in the formation and 
recirculation of bile acids may be impacted in patients with NASH.
Intestinal flora mediate deconjugation of bile acids as well as conversion of primary to 
secondary bile acid species. While many intestinal microbes deconjugate bile acids, only a 
few possess the ability to dehydroxylate primary to secondary bile acids.[7] Therefore, 
changes in intestinal flora, especially in the colon where most bacteria that are able to 
dehydroxylate bile acids reside, could substantially alter systemic concentrations of 
conjugated and/or secondary bile acids returned to the liver through enterohepatic 
recirculation. Intestinal dysbiosis in NAFLD has been well documented.[6,15] Changes in 
the fecal microbiota in NAFLD involve some of the most prominent phylums, including 
Firmicutes, Bacteroidetes and Proteobacteria. Many of the individual species within these 
groups are able to deconjugate and/or dehydroxylate bile acids, including Bacteroides, 
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Clostridium and Escherichia, which may lead to increased circulating unconjugated 
secondary bile acid species. Furthermore, the variability observed in pre- and post-prandial 
bile acid concentrations may be influenced by intra-subject variation in GI flora.
Higher systemic concentrations of secondary bile acids in this study are consistent with 
altered intestinal microbiota and increased production of secondary bile acids, with the 
majority present as conjugated species. This finding could be due to decreased 
deconjugation of secondary bile acids by intestinal microbiota, but also is likely influenced 
by increased hepatic conjugation with taurine and glycine. Bile acid coenzyme A:amino acid 
N-acyltransferase enzyme (BAAT) is the primary enzyme responsible for conjugation of bile 
acids with taurine and glycine.[23] Indeed, both BAAT expression and availability of taurine 
as a cofactor were increased in liver biopsies from patients with NASH compared to subjects 
without liver disease.[24] Taken together, our findings support the theory that altered 
intestinal microbiota and increased hepatic conjugation of secondary bile acids leads to a 
greater systemic burden of secondary bile acids and potential for toxic effects.
Under normal physiologic conditions bile acids appear to function as hormones, which 
allows communication between the liver, intestine, and other organ systems. Bile acids are 
ligands for FXR, TGR5, and PXR, which are involved in diverse functions including 
prevention of intestinal bacterial overgrowth[25], stimulating the release of glucagon-like 
peptide-1[26], and regulating adipose and muscle tissue energy expenditure.[27] At high 
levels, bile acids are able to activate inflammatory- and oxidative stress-mediated cell death 
pathways[28]; the more hydrophobic bile acid species (e.g., DCA and LCA) appear to be 
more potent activators of these pathways.[29] Therefore constant or repeated activation of 
these cell death pathways could result in prolonged low-grade inflammation and selection 
for resistant cells and cancer initiation. In this study, patients with NASH had increased total 
and secondary bile acid concentrations under fasting conditions and at all post-prandial time 
points; post-prandial exposure to DCA species was statistically significantly increased 2-
fold. Additionally, unconjugated LCA species showed a trend toward higher concentrations 
in patients with NASH at pre- and post-prandial time points. Furthermore, taurine and 
glycine conjugation of LCA, which aids in LCA detoxification, appears to be decreased as 
evidenced by the decreased exposure to glycine- and taurine-conjugated LCA species 1 to 2 
hours following a high fat meal. This suggests bile acids may be involved in the 
pathogenesis of liver injury and potentially initiation of cancerous activity, particularly in the 
colon or liver where the secondary bile acids concentrate.[2,30]
OPLS-DA plots show a clear differentiation in bile acid species at fasting and post-prandial 
time points. These findings suggest that, in addition to bile acid species playing a role in the 
pathogenesis of NASH, bile acid profiles may be useful in the diagnosis of NASH. 
Variations in profiles could reflect pre-cirrhotic decrements in liver synthetic and excretory 
function. Recently, altered hepatic transporter-mediated disposition of morphine glucuronide 
was shown to be positively correlated with NASH severity.[13] Progression of NAFLD from 
simple steatosis to NASH is correlated with decreased hepatic uptake and increased hepatic 
efflux transport protein expression.[12] These transporters are involved in the disposition of 
both exogenously administered drugs as well as endogenous substrates, including bile acids. 
Therefore, future well-controlled studies should evaluate the diagnostic ability of changes in 
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the bile acid metabolome to detect pre-cirrhotic liver dysfunction in patients with NASH and 
simple steatosis.
In conclusion, this study demonstrates patients with NASH have a distinct shift in fasting 
circulating bile acids that is exaggerated in the post-prandial time period. This shift results in 
a more hydrophobic bile acid profile that may influence and/or precipitate NAFLD 
progression, and has implications in the diagnosis and staging of NASH. Bile acid 
derivatives and modulators are being evaluated for the treatment of NAFLD/NASH. Further 
research is vital for understanding the potential role of endogenous bile acids in NAFLD 
progression and the benefit these new agents may afford.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors would like to sincerely thank Drs. Nathan D. Pfeifer, Mary F. Paine, and Dhiren R. Thakker for 
insightful discussions throughout the development, conduct and analysis of this study. The authors also would like 
to thank Kevin B. Harris and Dr. Eleftheria Tsakalozou for assistance with study conduct and data management, and 
Lisa Hardee for assistance performing FibroScan® measurements. Phoenix WinNonlin software was generously 
provided to the Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, 
by Certara as a member of the Pharsight Academic Center of Excellence Program.
Financial Support: This project was supported in part by the National Institutes of Health, National Center for 
Advancing Translational Sciences (NCATS), through award number 1UL1TR001111, National Institute of General 
Medical Sciences through award number R01 GM041935 [K.L.R.B], an Amgen Predoctoral Fellowship in 
Pharmacokinetics and Drug Disposition [B.C.F.], and Quintiles Pharmacokinetics/Pharmacodynamics Fellowships 
[C.K.J.]. The content is solely the responsibility of the authors and does not necessarily represent the official views 
of the NIH, Amgen or Quintiles.
Abbreviations (as they appear)









FXR Farnesoid X Receptor
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OPLS-DA Orthogonal Partial Lease Squares-Discriminant Analysis
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Serum bile acid concentrations at screening and on study day by conjugation status in 
healthy subjects (grey, n=15) and patients with NASH (black, n=7). Total bile acid 
concentrations represent the molar sum of unconjugated, glycine-, taurine and sulfate-
conjugated bile acids. Data are presented as mean (nM) and standard error of the mean. 
*p<0.05 NASH vs. Healthy
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Serum bile acid species at screening and on study day depicted as concentration vs. time 
profiles in healthy subjects (grey circles, n=15) and patients with NASH (black squares, 
n=7). Post-prandial exposure calculated as the area under the serum concentration-time 
profile from 0–120 min (AUCpp) is reported. Data are presented as mean (nM or μM×min) 
and standard error of the mean. *p<0.05 NASH vs. Healthy
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Serum total unconjugated (left) and glycine and taurine-conjugated (right) LCA bile acid 
species in healthy subjects (grey circles, n=15) and patients with NASH (black squares, 
n=7). Post-prandial exposure calculated as the area under the serum concentration-time 
profile from 0–120 min (AUCpp) is reported. Data are presented as mean (nM or μM×min) 
and standard error of the mean.
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Relative abundance of bile acids in healthy subjects (grey, n=15) and patients with NASH 
(black, n=7) as a percentage of total serum bile acid concentrations. Data are presented as 
mean (%) and standard error of the mean.
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Urinary excretion of bile acid species in healthy subjects (grey, n=13) and patients with 
NASH (black, n=7). Data are presented as mean (nmoles) and standard error of the mean.
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Scores plots of the OPLS-DA models of bile acid profiles at each sample time in patients 
with NASH (black diamonds) compared to healthy subjects (grey circles) under fasting 
conditions (screening and pre-prandial) and following a high fat meal (30, 60, 90 and 120 
min post-prandial).
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Table 1
Demographic characteristics, serum chemistries, insulin resistance and liver biopsy grade of study participants.
Parameter Healthy (n=15) NASH (n=7)a
Sex Men : Women 7:8 3:4
Ethnicity Hispanic : Non-Hispanic 1:14 1:6
Race White : Black 13:2 7:0
Age (years) 43 (12) 48 (10)
Body weight (kg) 74 (15) 93 (17)*
Body mass index (kg/m2) 25 (2.7) 32 (5.2)*
Creatinine (mg/dL) 0.81 (0.13) 0.80 (0.22)
ALT (U/L) 33 (11) 75 (36)*
ALP (U/L) 64 (13) 80 (14)*
Albumin (g/dL) 4.3 (0.3) 4.5 (0.4)
Total Bilirubin (mg/dL) 0.63 (0.21) 0.81 (0.29)
Cholesterol (mg/dL) 192 (40) 190 (48)
Triglycerides (mg/dL) 96 (49) 253 (98)*
HDL (mg/dL) 67 (26) 37 (5)*
LDL, calculated (mg/dL) 105 (35) 101 (47)
Leptin (ng/mL) 9.1 (7.9) 31 (30)*
Osteopontin (ng/mL) 19 (16) 30 (9.8)
Fasting Glucose (mg/dL) 86 (8) 124 (16)*
Serum Insulin (μIU/mL) 7.6 (2.6) 40 (27)*
HOMA-IR 1.6 (0.6) 13 (8.7)*
Total NAS Score N/A 5 (4–6)
 Steatosis N/A 2 (1–3)
 Hepatocyte Ballooning N/A 2 (1–3)
 Inflammation N/A 1 (0–2)
Fibrosis N/A 1 (0–3)
NAS + Fibrosis N/A 7 (4–8)
FibroScan® Liver Stiffness (kPa) 4.14 (0.97) 13.9 (8.13)*
Data presented as mean (SD); biopsy scoring presented as median (range)
a
Some demographic data were reported previously as part of a pharmacokinetic study [13]
ALT; alanine aminotransferase
ALP; alkaline phosphatase
HDL; high-density lipoprotein cholesterol
LDL; low-density lipoprotein cholesterol
NAS: non-alcoholic fatty liver disease activity score
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HOMA-IR; homeostasis model for assessing insulin resistance
N/A; not applicable
*
P < 0.05, Student’s two-tailed t-test comparing healthy subjects to patients with NASH
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Table 2
Bile acids excreted in urine over 2-hour post-prandial period in healthy subjects and patients with NASH.
Mass Excreted over Post-prandial Period
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Mass Excreted over Post-prandial Period

























Presented as mass excreted (nmoles) mean (SEM), n=13 Healthy and n=7 NASH
*
: P<0.05 t-test between healthy and NASH
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